25-Gauge Microincision Vitrectomy to Treat Vitreoretinal Disease in Glaucomatous Eyes after Trabeculectomy. (22nd April 2014)

• Record Type: Journal Article
• Authors: Kunikata, Hiroshi; Aizawa, Naoko; Fuse, Nobuo; Abe, Toshiaki; Nakazawa, Toru
• Other Names: Farah Michel E. Academic Editor.
• Is Part Of: Journal of ophthalmology. Volume 2014(2014)
• Publication Date: 2014-04-22
• Subjects: Ophthalmology -- Periodicals; Eye Diseases; Ophthalmology; Ophthalmology; Electronic journals; Periodicals; Periodicals; Fulltext; Internet Resources; Periodicals; 617.7
• DOI: 10.1155/2014/306814
• Languages: English
• ISSNs: 2090-004X

Abstract

Abstract : Purpose . To determine the feasibility of using 25-gauge microincision vitrectomy surgery (25GMIVS) to treat vitreoretinal disease in glaucomatous eyes which have previously undergone trabeculectomy (TLE). Methods . A consecutive, interventional case series. We performed 25GMIVS in 15 glaucomatous eyes that had undergone TLE. Follow-up period was 11.5 months. Results . 25GMIVS was successfully used and led to improvement in visual acuity (P < 0.01 ). We performed 25GMIVS for proliferative diabetic retinopathy with neovascular glaucoma in 53% of eyes (8 of 15). Although 3 eyes needed further TLE following 25GMIVS, final IOP was below 21 mmHg in all eyes except one eye (93%) and was comparable to pre-25GMIVS IOP (P = 0.20 ) without an increase in the number of glaucoma medications (P = 0.14 ). Conclusions . 25GMIVS is a feasible treatment for vitreoretinal disease in eyes with preexisting TLE, effective in both significantly improving BCVA and preserving the filtering bleb, while not excluding further glaucoma surgery.